Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis
about
sameAs
NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinomaTreatment for Barrett's oesophagusBarrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesisEffects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysisRecurrent Barrett's esophagus and adenocarcinoma after esophagectomyA Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent CancersRole of nitric oxide in the pathogenesis of Barrett's-associated carcinogenesisThe stomach in health and diseaseEarly events during neoplastic progression in Barrett's esophagusEpidemiology of Barrett's Esophagus and Esophageal AdenocarcinomaRisk factors for neoplastic progression in Barrett's esophagusBarrett's oesophagus: frequency and prediction of dysplasia and cancerSystematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinomaWhat are all the things that aspirin does?Should aspirin be used to counteract 'salicylate deficiency'?Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysisDo nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysisAspirin induces apoptosis in oesophageal cancer cells by inhibiting the pathway of NF-kappaB downstream regulation of cyclooxygenase-2The effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E2 production in patients with Barrett's oesophagusChemoprevention in gastrointestinal cancers: current statusNon-steroidal anti-inflammatory drugs, lower oesophageal sphincter-relaxing drugs and oesophageal cancer. A case-control studyReview article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagusUse of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancersOptimizing cardiovascular and chemopreventive benefits of aspirin: what role for the proton-pump inhibitors?Molecular changes in the progression of Barrett's oesophagusEnvironmental causes of esophageal cancerDietary Inflammatory Index and Risk of Esophageal Squamous Cell Cancer in a Case-Control Study from IranUse of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control studyThe bitter barricading of prostaglandin biosynthesis pathway: understanding the molecular mechanism of selective cyclooxygenase-2 inhibition by amarogentin, a secoiridoid glycoside from Swertia chirayita.Life history trade-offs in cancer evolutionDevelopment, calibration, and validation of a U.S. white male population-based simulation model of esophageal adenocarcinoma.NSAIDs modulate clonal evolution in Barrett's esophagus.Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysisOverexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitorsExercise and the Prevention of Oesophageal Cancer (EPOC) study protocol: a randomized controlled trial of exercise versus stretching in males with Barrett's oesophagus.Low grade dysplasia in Barrett's esophagus: Should we worry?Risk factors for the development of oesophageal adenocarcinoma in Barrett's oesophagus: a UK primary care retrospective nested case-control study.Glutathione Peroxidase 7 Suppresses Bile Salt-Induced Expression of Pro-Inflammatory Cytokines in Barrett's Carcinogenesis.Loss of glutathione peroxidase 7 promotes TNF-α-induced NF-κB activation in Barrett's carcinogenesis.Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.
P2860
Q21563424-23EDEF95-3903-480A-837F-2B4644D6D19FQ24240701-BC8F8A6D-EB82-424F-AC2B-D3474BF0912AQ24602426-CEC3903D-E032-49B4-A3E2-114A51FC186FQ24796323-8DC4A45B-4539-44E9-A659-05F141B3B44EQ24805185-E24A393F-A649-4547-8867-4BAB88BB6FC6Q26739665-320F382A-7CF9-445A-91DB-0DF335515B45Q26766641-20174887-F925-4AB9-8155-EA8D768E034AQ26784036-0D70F8CA-62B7-4A06-9056-B7146696258EQ26825349-B6BE0C8B-FED5-492B-AAD8-BFD3389C8405Q26825742-36A41BAB-649B-4C5E-9EA0-D66ED93C4A87Q27002062-E77E4B71-43ED-40DD-9DE4-44BE11609B62Q28080794-0291CF21-3850-4971-A03D-9F8A49F6CD20Q28085367-4A786FA4-41BA-45B0-AC19-59E1ED995782Q28165288-95225A57-1F48-47D0-B32E-16FEDF4DE800Q28166200-0453D3BA-57DD-44FF-8BD1-AC85D06F862AQ28166676-C547C58A-3236-48C5-AA94-552A92E1AB6CQ28185207-D201DF61-F592-4355-A434-D14538766E76Q28193816-11A28E51-F41A-4A18-88A8-73B02507AB78Q28196272-02F531C0-71C5-4B5D-8E08-21C3A5295199Q28196514-E4A93D4E-A65F-4EC8-A489-86CEE29B1CAEQ28212536-E300392B-C570-4E99-8F3F-E6DF1450EC0FQ28214018-150CF3DA-0833-4DD2-AFAA-FD09CA078030Q28218710-1021CB31-C8C7-48A5-9082-E9F158BFD3A2Q28218738-748836EB-72C6-46C7-A000-134D02B68BAEQ28219148-E391E013-F3D3-48D3-A67A-4427ED305A1BQ28388848-6BFC0B2A-78BC-4B7A-AD4A-694D1F2E7640Q28391358-8E05C211-4B28-4080-9915-598EBD72AF00Q28476849-839A7C3E-85C2-4CF2-B8C3-9464350116FBQ28540582-6E97D697-9E04-46C7-9107-CBB01E986486Q28657962-D0CD0D02-156F-4FD6-87A3-365929A9BA4AQ30979196-D4061C7D-F01C-4585-BC84-B6E45E7871D9Q31119674-8AF2AE1F-D1C4-4080-BFEF-CC3106738127Q33555216-EE869907-C3E5-4616-8EDD-0B29B0A1008EQ33584254-F7784FED-5012-4CA3-8AE4-943462C69E2BQ33605428-46030704-5E39-418E-B9BD-1EA57A5691EFQ33628118-D1568A95-CB39-455F-89F8-24BA3EBF8D4CQ33695661-9F6E84A6-6B22-4E7C-8F9C-CBBCDBE199DFQ33794355-A03ADC96-16C6-4ECC-B12B-1067EDD2E913Q33827698-2F16E0E0-704D-4B02-A5E2-1431E6ACAB1FQ33905941-7FB6A5CE-C812-401A-9548-381C48049A1C
P2860
Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Protective association of aspi ...... matic review and meta-analysis
@ast
Protective association of aspi ...... matic review and meta-analysis
@en
Protective association of aspi ...... matic review and meta-analysis
@nl
type
label
Protective association of aspi ...... matic review and meta-analysis
@ast
Protective association of aspi ...... matic review and meta-analysis
@en
Protective association of aspi ...... matic review and meta-analysis
@nl
prefLabel
Protective association of aspi ...... matic review and meta-analysis
@ast
Protective association of aspi ...... matic review and meta-analysis
@en
Protective association of aspi ...... matic review and meta-analysis
@nl
P2093
P31
P3181
P356
P1433
P1476
Protective association of aspi ...... matic review and meta-analysis
@en
P2093
Douglas A Corley
Karla Kerlikowske
Patricia Buffler
Rajiv Verma
P3181
P356
10.1053/GAST.2003.50008
P407
P577
2003-01-01T00:00:00Z